BLSM

Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 09, 7:07 AMBlossomHill gets positive FDA End-of-Phase 1 feedback for BH-30643, backing 50 mg BID Phase 2 dose and registrational-intent SOLARA-2 trial in EGFR C797S+ NSCLC

Peers: AVBP CGEM ORIC BDTX NUVB KURA RLAY IDYA ERAS TNGX

| Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	499.34M
Enterprise Value	684.15M
Income	-
Sales	-
Book/sh	-5.50
Cash/sh	3.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.26
Current Ratio	5.26
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.89
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 18 BMO
EPS/Sales Surpr.	-844.92% -

Insider Own	28.93%
Insider Trans	20.65%
Inst Own	21.33%
Inst Trans	18.11%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	8.89%
SMA50	-13.72%
SMA200	-12.30%
Trades

Shs Outstand	31.78M
Shs Float	22.59M
Short Float	2.61%
Short Ratio	2.96
Short Interest	0.59M
52W High	27.99 -43.87%
52W Low	11.02 42.56%
Volatility	15.52% 12.02%
ATR (14)	1.73
RSI (14)	51.72
Beta	-
Rel Volume	0.69
Avg Volume	199.10K
Volume	85,302

Perf Week	26.90%
Perf Month	1.49%
Perf Quarter	-3.91%
Perf Half Y	-
Perf YTD	-0.25%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.40
Prev Close	14.24
Price	15.71
Change %	10.32%

Consensus

Strong Buy

Avg. Price Target

$35.40

Implied Upside

+125.3%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 01, 2026	Initiated	JJP Morgan	Overweight	$28	+78.2%
Sep 01, 2026	Initiated	HH.C. Wainwright	Buy	$35	+122.8%
Sep 01, 2026	Initiated	GGuggenheim	Buy	$30	+91.0%

Nov-09-26 07:00AM	BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC (GlobeNewswire) +7.11%
Nov-04-26 07:00AM	BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-03-26 07:00AM	BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference (GlobeNewswire)
Oct-22-26 07:00AM	BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-28-26 07:00AM	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer (GlobeNewswire) +8.05%
07:00AM	Loading…
Sep-18-26 07:00AM	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Sep-15-26 10:13AM	BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update (InvestorsHub)
07:00AM	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer (GlobeNewswire)
Sep-03-26 07:00AM	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Sep-01-26 07:00AM	BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer (GlobeNewswire)
Aug-18-26 07:00AM	BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC (GlobeNewswire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORDON CARL L	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:46 PM
ORBIMED ADVISORS LLC	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:43 PM
Schmid John P.	Director	Aug 10 '26	Buy	16.00	6,000	96,000	6,000	Aug 10 06:35 PM
Chen Bihua	Director	Aug 10 '26	Buy	16.00	312,500	5,000,000	3,614,034	Aug 10 06:32 PM
Keyes Jason A	Chief Financial Officer	Aug 10 '26	Buy	16.00	700	11,200	700	Aug 10 06:27 PM
Liptak Vincent Paul	General Counsel	Aug 07 '26	Buy	15.80	2,500	39,500	109,212	Aug 10 06:26 PM
Liptak Vincent Paul	General Counsel	Aug 10 '26	Buy	16.00	2,200	35,200	111,412	Aug 10 06:26 PM

Blossomhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded on June 22, 2020 and is headquartered in San Diego, CA.

Ph.D.Dr. Yishan Li M.B.A.

Scientific FounderDr. Jingrong Jean Cui Ph.D.

CFO & Executive VPMr. Jason A. Keyes M.B.A.

Chief Medical Officer & Executive VPDr. Geoff Oxnard M.D.

M.B.A.Dr. Vincent Liptak J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

BlossomHill Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.